Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upfront stereotactic radiosurgery added to encorafenib + binimetinib + pembrolizumab for BRAF V600-mutant melanoma with brain metastases
2021-006331-26Phase 2Active
- Sponsor
- Unicancer
- Start
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of encorafenib, binimetinib and pembrolizumab in melanoma and brain metastases (2 arms), sponsored by Unicancer. Primary endpoint: Intracranial progression-free survival. Started Nov 2023; status: active.
02
Drugs
03
Conditions
melanomabrain metastases
Beyond the preview
Go deeper on 2021-006331-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006331-26.